Ygion Biomedical, a Vienna, Austria-based company dedicated to developing individualized neoantigen-based cancer vaccines, raised €15M in Series A funding.
Backers included an undisclosed Austrian private investor.
The company intends to use the funds to further develop its YGNITETM technology platform and advance the lead program YG-01 into preclinical and clinical development.
Led by CEO Dr. Wolfgang Fischl, and Dr. Geert Mudde, Chief Technology Officer, Ygion Biomedical is focused on developing individualized “plug-and-play” cancer vaccines through a proprietary suite of technologies to identify, produce and target the delivery of relevant peptide neoepitopes resulting in precise targeted activation of the patient’s immune system. Its YGNITE™ platform combines sequencing, bioinformatics and the proprietary CARGONAUT™ vaccine platform to deliver neoepitope peptide vaccines tailored for each tumor and each patient.
YGION’s lead program YG-01 is currently in preclinical development.
FinSMEs
23/05/2024